Navigation Links
Cyberonics Names Bryan D. Olin, Ph.D. Vice President, Quality
Date:5/18/2009

HOUSTON, May 18 /PRNewswire-FirstCall/ -- Cyberonics, Inc. (Nasdaq: CYBX) today announced that Bryan D. Olin, Ph.D., joined Cyberonics as Vice President, Quality, effective on May 18, 2009. Dr. Olin will lead all of the company's quality programs.

Dr. Olin joins Cyberonics from Zeltiq Aesthetics, an aesthetics device firm in California, where he served as Senior Director, Quality Assurance, since October 2007. Prior to Zeltiq, Dr. Olin was employed as Executive Director, Failure Analysis, Product Quality Services and Product Safety with Cordis Corporation, a Johnson & Johnson company. Dr. Olin spent five years with another Johnson & Johnson company, LifeScan, as the Manager, Statistical Engineering; Senior Program Manager, QA; Director, Complaint Handling and QA Laboratories; and Director, Clinical Biometrics and Complaint Management. Dr. Olin began his business career as a Statistician for Procter & Gamble, providing statistical support to a diverse set of internal clients in R&D and manufacturing.

"Bryan brings substantial expertise in quality management that will be helpful in all aspects of our regulated business, including manufacturing and product development," said Dan Moore, Cyberonics' President and Chief Executive Officer. "He has extensive experience with regulatory inspections and submissions, complaint handling, CAPAs and clinical study design. We are pleased to have Bryan joining our team to lead the global quality system and programs."

Dr. Olin received a B.S. in Mathematics from the University of Kansas. He was awarded a Masters of Science and his Ph.D. in Statistics from Iowa State University. Dr. Olin served as an Adjunct Assistant Professor of Industrial Pharmacy at the University of Cincinnati for three years.

About Cyberonics, Inc. and VNS Therapy(TM)

Cyberonics, Inc. (NASDAQ: CYBX) is a medical technology company with core expertise in neuromodulation. The company developed and markets the Vagus Nerve Stimulation (VNS) Therapy(TM) System, which is FDA-approved for the treatments of refractory epilepsy and treatment-resistant depression. The VNS Therapy System uses a surgically implanted medical device that delivers pulsed electrical signals to the vagus nerve. Cyberonics markets the VNS Therapy System in selected markets worldwide.

Additional information on Cyberonics, Inc. and VNS Therapy(TM) is available at www.cyberonics.com and www.vnstherapy.com.

Contact information

    Greg Browne, CFO
    Cyberonics, Inc.
    100 Cyberonics Blvd.
    Houston, TX 77058
    Main:  (281) 228-7262
    Fax:  (281) 218-9332
    ir@cyberonics.com


'/>"/>
SOURCE Cyberonics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cyberonics Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2009 Financial Results
2. Cyberonics Continues Strong Sales Growth and Profitability in Fiscal 2009 Third Quarter
3. Cyberonics Announces Conference Call to Discuss Fiscal Year 2009 Third Quarter Financial Results
4. Cyberonics Names Milton M. Morris, Ph.D. Vice President, Research & Development
5. Cyberonics to Present at Piper Jaffray 20th Annual Health Care Conference
6. Cyberonics Reports Strong Sales Growth and Profitability in Fiscal 2009 Second Quarter
7. Cyberonics Announces Conference Call to Discuss Fiscal Year 2009 Second Quarter Financial Results
8. Cyberonics Provides Business Update Based on Final Ambulatory Payment Classification Rate Change Announcement by CMS
9. Cyberonics Corporate Headquarters Fully Operational Following Hurricane Ike
10. Cyberonics to Present at UBS Global Life Sciences Conference
11. Cyberonics to Present at Canaccord Adams 28th Annual Global Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... ... TherapySites, the leading website and online marketing ... Association. This new relationship allows TherapySites to continue to extend their online ... and promotional offers. , "TCA is extremely excited about this new partnership, as ...
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is underway. ... ambulance transport experience for the millions of people who require these medical transport ... taxi industry through the use of technology. Now, SmartEMS has put forth an ...
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer ... they remain in the eye of the beholder, according to experts who offered insights ... American Journal of Managed Care. For the full issue, click here . , ...
(Date:6/26/2016)... , ... June 26, 2016 , ... Pixel Film Studios ... X. , "Film editors can give their videos a whole new perspective by using ... - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different ...
(Date:6/26/2016)... ... ... legally blind and certified personal trainer is helping to develop a weight loss fitness plan ... fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
Breaking Medicine Technology: